Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C

Internal Medicine

Volumn 48, Issue 16, 2009, Pages 1387-1390

  Ogihara, Takehide ^a   Katagiri, Hideki ^a   Yamada, Tetsuya ^a   Kudo, Hirohito ^a   Imai, Junta ^a   Ishigaki, Yasushi ^a   Hinokio, Yoshinori ^a   Yamagiwa, Yoko ^a   Ueno, Yoshiyuki ^a   Shimosegawa, Tooru ^a   Oka, Yoshitomo ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anti glutamate acid decarboxylase (GAD) antibody; Anti insulinoma associated antigen (IA) 2 antibody; Autoimmune disease; Human leukocyte antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BUFORMIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PEGINTERFERON ALPHA; RIBAVIRIN; THYROID PEROXIDASE ANTIBODY; VIRUS RNA;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TASTE DISORDER;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 70349654138     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2220     Document Type: Article

References (23)

1. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 336: 347-356, 1997.
2. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005.
3. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract 30: 237-241, 1995.
4. Uto H, Matsuoka H, Murata M, et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 49: 101-106, 2000.
5. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 28: 39-46, 2008.
6. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 18: 689-692, 2006.
7. Tanaka J SK, Shiraki K, Beppu T, et al. Type 1 diabetes mellitus proveked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Inter Med 47: 747-749, 2008.
8. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578, 1986.
9. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363-367, 1992.
10. Nadir F, Faqiuoli S, Wright HI, et al. Rheumatoid arthritis: a complication of interferon therapy. J Okla State Med Assoc 87: 228-230, 1994.
11. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 116: 51-53, 1992.
12. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68: 1536-1537, 1991.
13. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340: 548, 1992.
14. Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat 7: 393-395, 2000.
15. Harris DM, Hespenheide EE, Dalkin AC, Kirk SE, Ellis DS, Caldwell SH. Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm. Am J Gastroenterol 95: 2995-2996, 2000.
16. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 353-360, 1985.
17. Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 157: 522-528, 1996.
18. Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44: 658-664, 1995.
19. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18: 549-558, 2003.
20. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 38: 641-647, 1989.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492, 1998.
22. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493-1499, 1998.
23. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 30: 376-382, 1999.